FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308394971> ?p ?o ?g. }

• W4308394971 abstract "<h3>Background</h3> Clinical studies have linked usage of progestins (synthetic progesterone) to breast cancer risk. However, little is understood regarding the role of native progesterone (P4), signaling through the progesterone receptor (PR), in breast tumor formation. Recently, we demonstrated that P4 treatment or PR overexpression can drive changes in immune cell populations in the murine mammary gland and that PR overexpression leads to increased development of mammary gland tumors in mice. Given these findings, we sought to investigate whether P4 impacts tumor growth and immune cell infiltration of mammary gland tumors. <h3>Methods</h3> To evaluate the effect of P4 on PR+ mammary gland tumor growth, orthotopic syngeneic mammary gland tumors were utilized. Briefly, mice were implanted with P4 (30mg) or placebo pellets and were injected with mammary gland tumor cells. After 28 days, tumors were excised and immunophenotyping was performed via flow cytometry. To determine the effect of anti-progestin treatment on mammary gland tumor growth and immune cell infiltration, two syngeneic mammary gland tumor models were used, in which mice were implanted with onapristone (30mg) or placebo pellets followed by mammary gland tumors. After 28 days, tumors were excised and immunophenotyping was performed via flow cytometry. The experiment was repeated in SCID mice to determine if effects of onpristone were immunologically mediated. <h3>Results</h3> In syngeneic mammary gland tumor models, P4 promoted tumor growth and impacted immune cell infiltration of PR+ mammary gland tumors. Numbers of tumor-infiltrating dendritic cells were decreased and exhausted T cells and regulatory T cells were increased with P4 treatment in PR+ tumors. Onapristone treatment led to significantly decreased tumor volumes in two syngeneic mammary gland tumor models and reversed the effect that P4 had on tumor-infiltrating regulatory T cells. To determine if inhibition of tumor growth by onapristone was immunologically mediated, SCID mice bearing PR+ mammary gland tumors were treated with onapristone. Results revealed a decreased ability of onapristone to inhibit tumor growth in SCID mice compared to immunocompetent mice, suggesting that inhibition of tumor growth is, in part, immunologically mediated. <h3>Conclusions</h3> These findings offer a novel mechanism of P4-driven mammary gland tumor development and provide rationale in investigating the usage of anti-progestin therapies to promote immune-mediated elimination of mammary gland tumors." @default.
• W4308394971 created "2022-11-11" @default.
• W4308394971 creator A5008662619 @default.
• W4308394971 creator A5011368708 @default.
• W4308394971 creator A5023207853 @default.
• W4308394971 creator A5027108690 @default.
• W4308394971 creator A5045631469 @default.
• W4308394971 creator A5047616979 @default.
• W4308394971 creator A5053154937 @default.
• W4308394971 creator A5059653866 @default.
• W4308394971 creator A5060398911 @default.
• W4308394971 creator A5078071350 @default.
• W4308394971 creator A5085929839 @default.
• W4308394971 creator A5086809027 @default.
• W4308394971 creator A5087800629 @default.
• W4308394971 creator A5089113899 @default.
• W4308394971 creator A5090752431 @default.
• W4308394971 date "2022-11-01" @default.
• W4308394971 modified "2023-09-25" @default.
• W4308394971 title "1109 Progesterone impacts the growth and immune cell infiltration of murine mammary gland tumors" @default.
• W4308394971 doi "https://doi.org/10.1136/jitc-2022-sitc2022.1109" @default.
• W4308394971 hasPublicationYear "2022" @default.
• W4308394971 type Work @default.
• W4308394971 citedByCount "0" @default.
• W4308394971 crossrefType "proceedings-article" @default.
• W4308394971 hasAuthorship W4308394971A5008662619 @default.
• W4308394971 hasAuthorship W4308394971A5011368708 @default.
• W4308394971 hasAuthorship W4308394971A5023207853 @default.
• W4308394971 hasAuthorship W4308394971A5027108690 @default.
• W4308394971 hasAuthorship W4308394971A5045631469 @default.
• W4308394971 hasAuthorship W4308394971A5047616979 @default.
• W4308394971 hasAuthorship W4308394971A5053154937 @default.
• W4308394971 hasAuthorship W4308394971A5059653866 @default.
• W4308394971 hasAuthorship W4308394971A5060398911 @default.
• W4308394971 hasAuthorship W4308394971A5078071350 @default.
• W4308394971 hasAuthorship W4308394971A5085929839 @default.
• W4308394971 hasAuthorship W4308394971A5086809027 @default.
• W4308394971 hasAuthorship W4308394971A5087800629 @default.
• W4308394971 hasAuthorship W4308394971A5089113899 @default.
• W4308394971 hasAuthorship W4308394971A5090752431 @default.
• W4308394971 hasBestOaLocation W43083949711 @default.
• W4308394971 hasConcept C121332964 @default.
• W4308394971 hasConcept C121608353 @default.
• W4308394971 hasConcept C126322002 @default.
• W4308394971 hasConcept C134018914 @default.
• W4308394971 hasConcept C142724271 @default.
• W4308394971 hasConcept C153400128 @default.
• W4308394971 hasConcept C196166836 @default.
• W4308394971 hasConcept C203014093 @default.
• W4308394971 hasConcept C2776187077 @default.
• W4308394971 hasConcept C2778001805 @default.
• W4308394971 hasConcept C502942594 @default.
• W4308394971 hasConcept C530470458 @default.
• W4308394971 hasConcept C553184892 @default.
• W4308394971 hasConcept C71924100 @default.
• W4308394971 hasConcept C86803240 @default.
• W4308394971 hasConcept C8891405 @default.
• W4308394971 hasConcept C97355855 @default.
• W4308394971 hasConceptScore W4308394971C121332964 @default.
• W4308394971 hasConceptScore W4308394971C121608353 @default.
• W4308394971 hasConceptScore W4308394971C126322002 @default.
• W4308394971 hasConceptScore W4308394971C134018914 @default.
• W4308394971 hasConceptScore W4308394971C142724271 @default.
• W4308394971 hasConceptScore W4308394971C153400128 @default.
• W4308394971 hasConceptScore W4308394971C196166836 @default.
• W4308394971 hasConceptScore W4308394971C203014093 @default.
• W4308394971 hasConceptScore W4308394971C2776187077 @default.
• W4308394971 hasConceptScore W4308394971C2778001805 @default.
• W4308394971 hasConceptScore W4308394971C502942594 @default.
• W4308394971 hasConceptScore W4308394971C530470458 @default.
• W4308394971 hasConceptScore W4308394971C553184892 @default.
• W4308394971 hasConceptScore W4308394971C71924100 @default.
• W4308394971 hasConceptScore W4308394971C86803240 @default.
• W4308394971 hasConceptScore W4308394971C8891405 @default.
• W4308394971 hasConceptScore W4308394971C97355855 @default.
• W4308394971 hasLocation W43083949711 @default.
• W4308394971 hasOpenAccess W4308394971 @default.
• W4308394971 hasPrimaryLocation W43083949711 @default.
• W4308394971 hasRelatedWork W2002315461 @default.
• W4308394971 hasRelatedWork W2016202130 @default.
• W4308394971 hasRelatedWork W2026301838 @default.
• W4308394971 hasRelatedWork W2044117464 @default.
• W4308394971 hasRelatedWork W2055663745 @default.
• W4308394971 hasRelatedWork W2155981800 @default.
• W4308394971 hasRelatedWork W2164950712 @default.
• W4308394971 hasRelatedWork W2325341235 @default.
• W4308394971 hasRelatedWork W4248212310 @default.
• W4308394971 hasRelatedWork W4252963116 @default.
• W4308394971 isParatext "false" @default.
• W4308394971 isRetracted "false" @default.
• W4308394971 workType "article" @default.